Effects of Interferon β1-a Administration in the First Versus Second Week of Treatment on Recovery in Patients with COVID-19: A Retrospective Study

Background: COVID-19, an acute respiratory disease caused and transmitted by SARS-COV-2 virus, has turned into a major global concern since 2019. In severe cases, the elevated levels of immune cells cause inappropriate responses. To date, no medications have been approved for COVID-19. Methods: The present retrospective cohort study was designed and conducted in Shahid Mohammadi Hospital, Bandar Abbas, Iran, in 2020. Eligible patients with confirmed COVID-19 based on PCR test were included (n = 200) and allocated to two groups to receive interferon β1-a (IFNβ1-a) either in the first or in the second week of treatment (IFN week 1 and IFN week 2 groups, respectively). The primary objective of this study was to compare the effectiveness of IFNβ1-a administration in the first and the second week of treatment on patient mortality. The secondary objective was to investigate the difference between the two groups in terms of laboratory data and length of hospitalization. The data were analyzed using Chi-square and Fisher’s exact tests. Results: The study population was divided into two equal groups. IFNw1 group received IFNβ1-a in the first week and IFNw2 group in the second week of treatment. The two groups matched in terms of baseline demographic data. The mortality rate was significantly lower in the IFNw1 group (13% vs. 18%; P-value = 0.01). At discharge, C-reactive protein (CRP) was clearly reduced in the IFNw1 group compared to the IFNw2 group (15 ± 12 vs. 24 ± 16; P-value = 0.02), but other lab variables did not show a significant difference between the two groups. Conclusions: There was a relationship between IFNβ1-a administration time and the trend of recovery in patients with moderate COVID-19. Administration of IFNβ1-a in the first days of treatment can reduce inflammatory factors and mortality rates in these patients.